Amersham In 1997, the biotechnology division of the company Pharmacia Biotech merged with
Amersham Life Science with the new merged entity being known as Amersham Pharmacia Biotech. In 2001, the company was renamed Amersham Biotech. In 2002, Pharmacia sold its share of the company to
Amersham plc. In 2004, Amersham Biosciences was acquired by
GE Healthcare. In 1998, the nutrition division of the company was sold to
Fresenius.
Monsanto Monsanto acquired the pharmaceutical company
G. D. Searle & Company in 1985. In 1998, Searle and the Monsanto Pharma Sector partnered with Pfizer to develop and promote
celecoxib, an anti-inflammatory drug used to treat arthritis. Branded as Celebrex, celecoxib was approved by the FDA in 1998. In December 1999, Pharmacia & Upjohn merged with the American biotechnology and medical company,
Monsanto and renamed itself Pharmacia. The company retained Monsanto's pharmaceutical division - then known as Searle - and spun off the remaining interests as the "new Monsanto". The newly merged pharmaceutical entity changed its name to Pharmacia Corp.
Pfizer In July 2002, Pharmacia Corp. and
Pfizer announced an agreement that Pfizer would purchase Pharmacia; control of celecoxib was often mentioned as a key reason for Pfizer's acquisition of Pharmacia. The deal was finalized in April 2003.
Later developments • The remnant of the Stockholm-based part of Pharmacia was partly spun off to
Biovitrum in 2001, which sold off its plasma products division to
Octapharma in 2002. • In 2004, the allergy-diagnostic division of Pharmacia was sold off as Pharmacia Diagnostics. Later in 2004, the Uppsala-based
ophthalmology division was sold to
Advanced Medical Optics. • In April 2006, Pharmacia Diagnostics changed its name to
Phadia, which ended the use of the
Pharmacia trademark. In September, Phadia was acquired by PPM Capital. The company's facilities in
Strängnäs Sweden are currently being expanded for the production of Genotropin, a
growth hormone.
Overview The following is an illustration of the company's mergers, acquisitions,
spin-offs and historical predecessors: }} ==References==